

# PHYTONADIONE- phytonadione injection, emulsion

Cipla USA Inc.

-----

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PHYTONADIONE INJECTABLE EMULSION safely and effectively. See full prescribing information for PHYTONADIONE INJECTABLE EMULSION.

PHYTONADIONE injectable emulsion, for intravenous, intramuscular, and subcutaneous use. Initial U.S. Approval: 1960

### WARNING-HYPERSENSITIVITY REACTIONS WITH INTRAVENOUS AND INTRAMUSCULAR USE

*See full prescribing information for complete boxed warning.*

**Fatal hypersensitivity reactions, including anaphylaxis, have occurred during and immediately after INTRAVENOUS and INTRAMUSCULAR injection of phytonadione injectable emulsion. Reactions have occurred despite dilution to avoid rapid infusion and upon first and subsequent doses. Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified. (5.1)**

### INDICATIONS AND USAGE

Phytonadione injectable emulsion is a vitamin K replacement indicated for the treatment of the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity.

- Anticoagulant-induced hypoprothrombinemia deficiency caused by coumarin or indanedione derivatives; (1.1)
- Hypoprothrombinemia due to antibacterial therapy; (1.1)
- Hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; (1.1)
- Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. (1.1)

Phytonadione injectable emulsion is indicated for prophylaxis and treatment of vitamin K-deficiency bleeding in neonates. (1.2)

### DOSAGE AND ADMINISTRATION

- Administer phytonadione injectable emulsion by the subcutaneous route, whenever possible. (2.1)
- When intravenous administration is unavoidable, inject the drug very slowly, not exceeding 1 mg per minute. (2.1)

### DOSAGE FORMS AND STRENGTHS

Injection: 2 mg/mL and 10 mg/mL single-dose vials. (3)

### CONTRAINDICATIONS

Hypersensitivity to any component of this medication. (4)

### WARNINGS AND PRECAUTIONS

- Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative: Use benzyl alcohol-free formulations in neonates and infants, if available. (5.1)
- Cutaneous Reactions: May occur with parenteral use. Discontinue drug and manage medically. (5.3)

### ADVERSE REACTIONS

Most common adverse reactions are cyanosis, diaphoresis, dizziness, dysgeusia, dyspnea, flushing, hypotension and tachycardia. (6)

**To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd at 1-866-604-3268, or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

### DRUG INTERACTIONS

Anticoagulants: May induce temporary resistance to prothrombin-depressing anticoagulants. (7)

### USE IN SPECIFIC POPULATIONS

- Pregnancy: If available, use the preservative-free formulation in pregnant women. (8.1)
- Lactation: If available, use the preservative-free formulation in lactating women. (8.2)
- Pediatric Use: The safety and effectiveness of phytonadione injectable emulsion in pediatric patients from 6 months to 17 years have not been established. (8.4)

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 1/2024**

---

## **FULL PRESCRIBING INFORMATION: CONTENTS\***

### **WARNING-HYPERSENSITIVITY REACTIONS WITH INTRAVENOUS AND INTRAMUSCULAR USE**

#### **1 INDICATIONS AND USAGE**

- 1.1 Treatment of Hypoprothrombinemia Due to Vitamin K Deficiency or Interference
- 1.2 Prophylaxis and Treatment of Vitamin K-Deficiency Bleeding in Neonates

#### **2 DOSAGE AND ADMINISTRATION**

- 2.1 Dosing Considerations
- 2.2 Recommended Dosage for Coagulation Disorders from Vitamin K Deficiency or Interference
- 2.3 Recommended Dosage for Prophylaxis and Treatment of Vitamin K Deficiency Bleeding in Neonates
- 2.4 Directions for Dilution

#### **3 DOSAGE FORMS AND STRENGTHS**

#### **4 CONTRAINDICATIONS**

#### **5 WARNINGS AND PRECAUTIONS**

- 5.1 Hypersensitivity Reactions
- 5.2 Risk of Serious Adverse Reaction in Infants due to Benzyl Alcohol Preservative
- 5.3 Cutaneous Reactions

#### **6 ADVERSE REACTIONS**

- 6.1 Clinical Trials and Post-Marketing Experience

#### **7 DRUG INTERACTIONS**

#### **8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use

#### **10 OVERDOSAGE**

#### **11 DESCRIPTION**

#### **12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

#### **13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### **16 HOW SUPPLIED/STORAGE AND HANDLING**

#### **17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## FULL PRESCRIBING INFORMATION

### **WARNING-HYPERSENSITIVITY REACTIONS WITH INTRAVENOUS AND INTRAMUSCULAR USE**

**Fatal hypersensitivity reactions, including anaphylaxis, have occurred during and immediately after intravenous and intramuscular injection of phytonadione injectable emulsion. Reactions have occurred despite dilution to avoid rapid intravenous infusion and upon first dose. Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified [see *Warnings and Precautions (5.1)*].**

## 1 INDICATIONS AND USAGE

### **1.1 Treatment of Hypoprothrombinemia Due to Vitamin K Deficiency or Interference**

Phytonadione injectable emulsion is indicated for the treatment of the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity:

- anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives;
- hypoprothrombinemia due to antibacterial therapy;
- hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis;
- other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates.

### **1.2 Prophylaxis and Treatment of Vitamin K-Deficiency Bleeding in Neonates**

Phytonadione injectable emulsion is indicated for prophylaxis and treatment of vitamin K-deficiency bleeding in neonates.

## 2 DOSAGE AND ADMINISTRATION

### **2.1 Dosing Considerations**

Whenever possible, administer phytonadione injectable emulsion by the subcutaneous route [see *Boxed Warning*]. When intravenous administration is unavoidable, inject the drug very slowly, not exceeding 1 mg per minute [see *Warnings and Precautions (5.1)*].

Monitor international normalized ratio (INR) regularly and as clinical conditions indicate. Use the lowest effective dose of phytonadione injectable emulsion.

The coagulant effects of phytonadione injectable emulsion are not immediate; improvement of INR may take 1-8 hours. Interim use of whole blood or component

therapy may also be necessary if bleeding is severe.

Whenever possible, administer benzyl alcohol-free formulations in pediatric patients [see *Warnings and Precautions (5.2), Use in Specific Populations (8.4)*].

When phytonadione injectable emulsion is used to correct excessive anticoagulant-induced hypoprothrombinemia, anticoagulant therapy still being indicated, the patient is again faced with the clotting hazards existing prior to starting the anticoagulant therapy. Phytonadione is not a clotting agent, but overzealous therapy with phytonadione injectable emulsion may restore conditions which originally permitted thromboembolic phenomena. Dosage should be kept as low as possible, and INR should be checked regularly as clinical conditions indicate.

## **2.2 Recommended Dosage for Coagulation Disorders from Vitamin K Deficiency or Interference**

The recommended dosage of phytonadione injectable emulsion is based on whether the hypoprothrombinemia is anticoagulant-induced (e.g., due to coumarin or indanedione derivatives) or non-anticoagulant-induced (e.g., due to antibiotics; salicylates or other drugs; factors limiting absorption or synthesis) as follows:

- Anticoagulant-Induced Hypoprothrombinemia: Phytonadione injectable emulsion 2.5 mg to 10 mg or more subcutaneously, intramuscularly, or intravenously. Up to 25 mg to 50 mg may be administered as a single dose.

Repeated large doses of phytonadione injectable emulsion are not warranted in liver disease if the initial response is unsatisfactory. Failure to respond to phytonadione injectable emulsion may indicate that the condition being treated is inherently unresponsive to phytonadione injectable emulsion.

- Hypoprothrombinemia Due to Other Causes (Non-Anticoagulation-Induced Hypoprothrombinemia): Phytonadione injectable emulsion 2.5 mg to 25 mg or more intravenously, intramuscularly, or subcutaneously. Up to 50 mg may be administered as a single dose.

Evaluate INR after 6-8 hours, and repeat dose if INR remains prolonged. Modify subsequent dosage (amount and frequency) based on the INR or clinical condition.

## **2.3 Recommended Dosage for Prophylaxis and Treatment of Vitamin K Deficiency Bleeding in Neonates**

### Prophylaxis of Vitamin K-Deficiency Bleeding in Neonates

The recommended dosage of phytonadione injectable emulsion is 0.5 mg to 1 mg within one hour of birth for a single dose.

### Treatment of Vitamin K Deficiency Bleeding in Neonates

The recommended dosage of phytonadione injectable emulsion is 1 mg given either subcutaneously or intramuscularly. Consider higher doses if the mother has been receiving oral anticoagulants.

A failure to respond (shortening of the INR in 2 to 4 hours) may indicate another diagnosis or coagulation disorder.

## **2.4 Directions for Dilution**

Dilute phytonadione injectable emulsion with 0.9% Sodium Chloride Injection, 5% Dextrose Injection, or 5% Dextrose and Sodium Chloride Injection. Avoid use of other diluents that may contain benzyl alcohol, which can cause serious toxicity in newborns or low birth weight infants [see *Warnings and Precautions (5.2)* and *Use in Specific Populations (8.4)*].

When diluted, start administration of phytonadione injectable emulsion immediately after dilution.

Discard unused portions of diluted solution as well as unused contents of the vial.

Protect phytonadione injectable emulsion from light at all times.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

### **3 DOSAGE FORMS AND STRENGTHS**

Injection: 2 mg/mL and 10 mg/mL single-dose vials.

### **4 CONTRAINDICATIONS**

Hypersensitivity to phytonadione or any other component of this medication [see *Warnings and Precautions (5.1)*].

### **5 WARNINGS AND PRECAUTIONS**

#### **5.1 Hypersensitivity Reactions**

Fatal and severe hypersensitivity reactions, including anaphylaxis, have occurred with intravenous or intramuscular administration of phytonadione injectable emulsion. Reactions have occurred despite dilution to avoid rapid intravenous infusion and upon first dose. These reactions have included shock, cardiorespiratory arrest, flushing, diaphoresis, chest pain, tachycardia, cyanosis, weakness, and dyspnea. Administer phytonadione injectable emulsion subcutaneously whenever feasible. Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified [see *Dosage and Administration (2.1)*].

#### **5.2 Risk of Serious Adverse Reaction in Infants due to Benzyl Alcohol Preservative**

Use benzyl alcohol-free formulations in neonates and infants, if available. Serious and fatal adverse reactions including "gaspings syndrome" can occur in neonates and infants treated with benzyl alcohol-preserved drugs, including phytonadione injectable emulsion. The "gaspings syndrome" is characterized by central nervous system depression, metabolic acidosis, and gasping respirations.

When prescribing phytonadione injectable emulsion in infants, consider the combined daily metabolic load of benzyl alcohol from all sources including phytonadione injectable emulsion (contains 9 mg of benzyl alcohol per mL) and other drugs containing benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known [see *Use in Specific Populations (8.1, 8.2 and 8.4)*].

### **5.3 Cutaneous Reactions**

Parenteral administration of vitamin K replacements (including phytonadione injectable emulsion) may cause cutaneous reactions. Reactions have included eczematous reactions, scleroderma-like patches, urticaria, and delayed-type hypersensitivity reactions. Time of onset ranged from 1 day to a year after parenteral administration. Discontinue phytonadione injectable emulsion for skin reactions and institute medical management.

## **6 ADVERSE REACTIONS**

The following serious adverse reactions are described elsewhere in the labeling:

- Hypersensitivity Reactions [*see Warnings and Precautions (5.1)*]
- Cutaneous Reactions [*see Warnings and Precautions (5.3)*]

### **6.1 Clinical Trials and Post-Marketing Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The following adverse reactions have been identified during post-approval use of phytonadione injectable emulsion. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiac Disorders: Tachycardia, hypotension.

General disorders and administration site conditions: Generalized flushing; pain, swelling, and tenderness at injection site.

Hepatobiliary Disorders: Hyperbilirubinemia

Immune System Disorders: Fatal hypersensitivity reactions, anaphylactic reactions.

Neurologic: Dysgeusia, dizziness.

Pulmonary: Dyspnea.

Skin and Subcutaneous Tissue Disorders: Erythema, pruritic plaques, scleroderma-like lesions, erythema perstans.

Vascular: Cyanosis.

## **7 DRUG INTERACTIONS**

### Anticoagulants

Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. Should this occur, higher doses of anticoagulant therapy may be needed when resuming anticoagulant therapy, or a change in therapy to a different class of anticoagulant may be necessary (i.e., heparin sodium).

Phytonadione injectable emulsion does not affect the anticoagulant action of heparin.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### Risk Summary

Phytonadione injectable emulsion contains benzyl alcohol, which has been associated with gasping syndrome in neonates. The preservative benzyl alcohol can cause serious adverse events and death when administered intravenously to neonates and infants. If phytonadione injectable emulsion is needed during pregnancy, consider using a benzyl alcohol-free formulation [see *Warnings and Precautions (5.2), Use in Specific Populations (8.4)*].

Published studies with the use of phytonadione during pregnancy have not reported a clear association with phytonadione and adverse developmental outcomes [see *Data*]. There are maternal and fetal risks associated with vitamin K deficiency during pregnancy [see *Clinical Considerations*]. Animal reproduction studies have not been conducted with phytonadione.

The estimated background risk for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

#### Clinical Considerations

##### *Disease-associated maternal and/or embryo/fetal risk*

Pregnant women with vitamin K deficiency hypoprothrombinemia may be at an increased risk for bleeding diatheses during pregnancy and hemorrhagic events at delivery. Subclinical maternal vitamin K deficiency during pregnancy has been implicated in rare cases of fetal intracranial hemorrhage.

#### Data

##### *Human Data*

Phytonadione has been measured in cord blood of infants whose mothers were treated with phytonadione during pregnancy in concentrations lower than seen in maternal plasma. Administration of vitamin K<sub>1</sub> to pregnant women shortly before delivery increased both maternal and cord blood concentrations. Published data do not report a clear association with phytonadione and adverse maternal or fetal outcomes when used during pregnancy. However, these studies cannot definitively establish the absence of any risk because of methodologic limitations including small sample size and lack of blinding.

##### *Animal Data*

In pregnant rats receiving vitamin K<sub>1</sub> orally, fetal plasma and liver concentrations increased following administration, supporting placental transfer.

### **8.2 Lactation**

## Risk Summary

Phytonadione injectable emulsion contains benzyl alcohol. If available, preservative-free phytonadione injectable emulsion is recommended when phytonadione injectable emulsion is needed during lactation [*see Warnings and Precautions (5.2), Use in Specific Populations (8.4)*].

Phytonadione is present in breastmilk. There are no data on the effects of phytonadione injectable emulsion on the breastfed child or on milk production. The developmental and health benefits of breastfeeding should be considered along with the clinical need for phytonadione injectable emulsion and any potential adverse effects on the breastfed child from phytonadione injectable emulsion or from the underlying maternal condition.

### **8.4 Pediatric Use**

The safety and effectiveness of phytonadione injectable emulsion for prophylaxis and treatment of vitamin K deficiency have been established in neonates. Use of phytonadione injection for prophylaxis and treatment of vitamin K deficiency is based on published clinical studies.

Serious adverse reactions including fatal reactions and the "gaspings syndrome" occurred in premature neonates and infants in the intensive care unit who received drugs containing benzyl alcohol as a preservative. In these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L). Additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Preterm, low-birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol.

When prescribing phytonadione injectable emulsion in infants consider the combined daily metabolic load of benzyl alcohol from all sources including phytonadione injectable emulsion (phytonadione injectable emulsion contains 9 mg of benzyl alcohol per mL) and other drugs containing benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known [*see Warnings and Precautions (5.2)*].

Whenever possible, use preservative-free phytonadione formulations in neonates. The preservative benzyl alcohol has been associated with serious adverse events and death in pediatric patients. Premature and low-birth weight infants may be more likely to develop toxicity.

## **10 OVERDOSAGE**

Hemolysis, jaundice, and hyperbilirubinemia in newborns, particularly in premature infants, may result from phytonadione injectable emulsion overdose.

## **11 DESCRIPTION**

Phytonadione is a vitamin K replacement, which is a clear, yellow to amber, viscous, odorless or nearly odorless liquid. It is insoluble in water, soluble in chloroform and

slightly soluble in ethanol. It has a molecular weight of 450.70.

Phytonadione is 2-methyl-3-phytyl-1, 4-naphthoquinone. Its empirical formula is  $C_{31}H_{46}O_2$  and its molecular structure is:

Phytonadione injectable emulsion, USP is a clear yellow, sterile, aqueous colloidal solution of vitamin  $K_1$ , with a pH of 4.5 to 7.0, available for injection by the intravenous, intramuscular, and subcutaneous routes. Phytonadione injectable emulsion, USP is available in 1 mg (2 mg/mL) and 10 mg (10 mg/mL) single-dose vials. Each milliliter of phytonadione injectable emulsion, USP contains the following inactive ingredients: 70 mg polyoxyl 35 castor oil, 37.5 mg dextrose monohydrate, 9 mg benzyl alcohol (preservative), and water for injection. Phytonadione injectable emulsion, USP contains glacial acetic acid for pH adjustment to 6.3 (4.5 – 7.0).

## **12 CLINICAL PHARMACOLOGY**

### **12.1 Mechanism of Action**

Phytonadione injectable emulsion aqueous colloidal solution of vitamin  $K_1$  for parenteral injection, possesses the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). Vitamin K is an essential cofactor for a microsomal enzyme that catalyzes the post-translational carboxylation of multiple, specific, peptide-bound glutamic acid residues in inactive hepatic precursors of factors II, VII, IX, and X. The resulting gamma-carboxy-glutamic acid residues convert the precursors into active coagulation factors that are subsequently secreted by liver cells into the blood.

In normal animals and humans, phytonadione is virtually devoid of activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function, that is, to promote the hepatic biosynthesis of vitamin K dependent clotting factors.

### **12.2 Pharmacodynamics**

The action of the aqueous dispersion, when administered intravenously, is generally detectable within an hour or two and hemorrhage is usually controlled within 3 to 6 hours. A normal INR may often be obtained in 12 to 14 hours.

## 12.3 Pharmacokinetics

### *Absorption:*

Phytonadione is readily absorbed following intramuscular administration.

### *Distribution:*

After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues.

### *Elimination:*

Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies of carcinogenicity, genotoxicity or impairment of fertility have not been conducted with phytonadione.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

Phytonadione injectable emulsion, USP is a clear yellow, sterile, aqueous colloidal solution and is supplied in a package of 10 as follows:

<b>NDC No.</b>	<b>Container</b>	<b>Amount of Phytonadione injectable emulsion In Container</b>	<b>Volume</b>	<b>Concentration</b>
69097-709-96	10 single-dose vials per carton	1 mg	0.5 mL	2 mg/mL
69097-708-96	10 single-dose vials per carton	10 mg	1 mL	10 mg/mL

Store at 20° to 25°C (68° to 77°F); [see USP Controlled Room Temperature].

Protect phytonadione injectable emulsion from light. Store container in closed original carton until contents have been used.

## 17 PATIENT COUNSELING INFORMATION

Inform the patient of the following important risks of phytonadione injectable emulsion:

### Serious Hypersensitivity Reactions

Advise the patient and caregivers to immediately report signs of hypersensitivity after receiving phytonadione injectable emulsion [see *Warnings and Precautions (5.1)*].

### Risk of Gasping Syndrome Due to Benzyl Alcohol

Advise the patient and caregivers of the risk of gasping syndrome associated with the use of products that contain benzyl alcohol (including phytonadione injectable emulsion) in neonates, infants, and pregnant women [*see Warnings and Precautions (5.2)*].

### Cutaneous Reactions

Advise the patient and caregivers to report the occurrence of new rashes after receiving phytonadione injectable emulsion. These reactions may be delayed for up to a year after treatment [*see Warnings and Precautions (5.3)*].

**Manufactured by:** Cipla Ltd., India

At M/s Immacule Lifesciences Pvt. Ltd. India

**Manufactured for:**

Cipla USA, Inc.

10 Independence Boulevard, Suite 300,

Warren, NJ 07059

**Revised:** 3 /2022

### **PACKAGE LABEL.PRINCIPAL DISPLAY PANEL**

NDC 69097-709-30                      RX Only

Phytonadione

Injectable Emulsion, USP

1 mg/0.5 mL

Neonatal Concentration

0.5 mL Single-Dose Vial

Contains no more

than 500 mcg/L

of aluminum.

Protect from Light.

Cipla

NDC 69097-709-30 Rx Only

**Phytonadione**  
Injectable Emulsion, USP

**1 mg/0.5 mL**

**Neonatal Concentration**

0.5 mL Single-Dose Vial  
Contains no more than  
500 mcg/L of aluminum.  
Protect from light.

**Cipla**



(01) 00369097709303

Code No.: HP/DRUGS/L/19/2312/MB

Mfd. by: **Cipla Ltd. India**  
At M/s Immacule  
Lifesciences Pvt. Ltd. India.  
Mfd. for: **Cipla USA, Inc.**  
Warren, NJ 07059

Rev. 11/2020

218343

LOT  
EXP.



NDC 69097-708-31 RX Only

Phytonadione

Injectable Emulsion, USP 10 mg/ mL

1 mL Single-Dose Vial

Contains no more than  
500 mcg/L of aluminum.

Protect from Light.

Cipla

NDC 69097-708-31 Rx Only

**Phytonadione**  
Injectable Emulsion, USP

**10 mg/mL**

1 mL Single-Dose Vial  
Contains no more than  
500 mcg/L of aluminum.  
Protect from light.

**Cipla**



(01) 00369097708313

Code No.: HP/DRUGS/L/19/2312/MB

Mfd. by: **Cipla Ltd. India**  
At M/s Immacule  
Lifesciences Pvt. Ltd. India.  
Mfd. for: **Cipla USA, Inc.**  
Warren, NJ 07059

Rev. 11/2020

218344

LOT  
EXP.



NDC 69097-709-96

RX Only

Phytonadione

Injectable Emulsion, USP

1 mg/0.5 mL

Neonatal Concentration

For INTRAMUSCULAR, SUBCUTANEOUS or  
INTRAVENOUS (with caution).


Protect from light.

Keep vials in carton until time of use.

10 X 0.5 mL vials per carton

Single-Dose Vials

Cipla



NDC 69097-708-96

RX Only

Phytonadione

Injectable Emulsion, USP

10 mg/mL

For INTRAMUSCULAR, SUBCUTANEOUS or  
INTRAVENOUS (with caution).


Protect from light.

Keep vials in carton until time of use.

10 X 1 mL vials per carton

Single-Dose Vials

Cipla



## PHYTONADIONE

phytonadione injection, emulsion

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:69097-709
<b>Route of Administration</b>	INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
PHYTONADIONE (UNII: A034SE7857) (PHYTONADIONE - UNII:A034SE7857)	PHYTONADIONE	1 mg in 0.5 mL

### Inactive Ingredients

Ingredient Name	Strength
POLYOXYL 35 CASTOR OIL (UNII: 6D4M1DAL6O)	
DEXTROSE MONOHYDRATE (UNII: LX22YL083G)	
BENZYL ALCOHOL (UNII: LKG8494WBH)	
WATER (UNII: 059QF0KO0R)	
ACETIC ACID (UNII: Q40Q9N063P)	

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:69097-709-96	10 in 1 CARTON	04/27/2022	
1		0.5 mL in 1 VIAL; Type 0: Not a Combination Product		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA214596	04/27/2022	

## PHYTONADIONE

phytonadione injection, emulsion

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:69097-708
Route of Administration	INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
PHYTONADIONE (UNII: A034SE7857) (PHYTONADIONE - UNII:A034SE7857)	PHYTONADIONE	10 mg in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
POLYOXYL 35 CASTOR OIL (UNII: 6D4M1DAL6O)	
DEXTROSE MONOHYDRATE (UNII: LX22YL083G)	
BENZYL ALCOHOL (UNII: LKG8494WBH)	
WATER (UNII: 059QF0KO0R)	
ACETIC ACID (UNII: Q40Q9N063P)	

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:69097-708-96	10 in 1 CARTON	04/27/2022	
1		1 mL in 1 VIAL; Type 0: Not a Combination Product		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA214596	04/27/2022	

**Labeler** - Cipla USA Inc. (078719707)

**Registrant** - Cipla Limited (650138746)

## Establishment

Name	Address	ID/FEI	Business Operations
Immacule Lifesciences Private Limited		650694503	manufacture(69097-708, 69097-709)

Revised: 1/2024

Cipla USA Inc.